Filing Flows › Comparisons › MREO vs UPB
Mereo BioPharma Group vs Upstream Bio: MREO and UPB compared
Mereo BioPharma Group is the larger company: $800K of revenue in its latest quarter (Q3 2026) against $773K for Upstream Bio (Q2 2026).
Where the money goes: MREO and UPB
Mereo BioPharma Group (MREO) · Q3 2026
Mereo BioPharma Group, Q3 2026: revenue $800K, operating margin -777.2%, net loss $5.9M, operating cash flow −$4.1M. The chart follows the revenue to costs, profit and cash.
Upstream Bio (UPB) · Q2 2026
Upstream Bio, Q2 2026: revenue $773K (-18% year over year), net loss $39.7M, operating cash flow −$35.6M. The chart follows the revenue to costs, profit and cash.
| Mereo BioPharma Group (MREO) | Upstream Bio (UPB) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $800K | $773K |
| Revenue growth, Y/Y | — | -18% |
| Operating margin | -777.2% | n/m |
| Net earnings | −$5.9M | −$39.7M |
| Net margin | -732.9% | — |
| Operating cash flow | −$4.1M | −$35.6M |
Questions
Which is bigger, Mereo BioPharma Group or Upstream Bio?
Mereo BioPharma Group is the larger company: $800K of revenue in its latest quarter (Q3 2026) against $773K for Upstream Bio (Q2 2026).
More: Mereo BioPharma Group earnings · how Mereo BioPharma Group makes money · Upstream Bio earnings · how Upstream Bio makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 9, 2026; 10-Q filed Aug 11, 2026). Fiscal quarters can end on different dates. Not investment advice.